Literature DB >> 33911420

Approach to a Patient with Cutaneous Malignancy in the Time of COVID-19 Pandemic.

Suvashis Dash1, Shivangi Saha1, Somesh Gupta2, Maneesh Singhal1.   

Abstract

The world is facing an unprecedented crisis of COVID-19 pandemic. This disease has weakened the economy, paralyzed the healthcare system, and worn out the human resources. Patients with cutaneous malignancy or skin cancer comprise a substantial part of the patient population and they need appropriate management of the cancer as they face the risk of COVID-19. In the wake of COVID-19 pandemic, the approach to management of cutaneous malignancy needs to be reassessed. The challenges in the management of skin cancer during COVID-19 are discussed in this article. Risk stratification considering the type and nature of malignancy, age, comorbidity, and treatment option is crucial in making the suggestions. Patient care, adequate infection control, safety of healthcare worker, and rational use of resources are the cruxes of management in this trying time. Copyright:
© 2020 Journal of Cutaneous and Aesthetic Surgery.

Entities:  

Keywords:  Basal cell carcinoma; COVID-19; cancer reconstruction; cutaneous malignancy; melanoma; skin cancer; squamous cell carcinoma

Year:  2020        PMID: 33911420      PMCID: PMC8061650          DOI: 10.4103/JCAS.JCAS_65_20

Source DB:  PubMed          Journal:  J Cutan Aesthet Surg        ISSN: 0974-2077


INTRODUCTION

The world is going through the devastating and unparalleled pandemic of COVID-19.[1] The disease is caused by an enveloped, single-strand RNA virus called corona virus. At the present day (April 13, 2020), data show that more than 18 million people have been infected and more than 114,000 have died of this disease.[2] People with skin cancers are of special concern during this pandemic. According to WHO, the burden of cutaneous cancers is gradually increasing. In past decades, the incidence of nonmelanoma and melanoma skin cancers has increased significantly. Worldwide the yearly incidence of nonmelanoma skin cancers is approximately 3 million and that of melanoma is 132,000.[34]

Healthcare challenges during COVID

The impact of COVID-19 is so devastating on the healthcare systems; even countries with world’s best healthcare infrastructures are struggling. The system is overburdened, resources are exhausted, and manpower is burnt out.

Challenges in skin cancer management

As such management of skin cancers is a challenge due to the following factors[56]: Late detection of the precursor lesions of cutaneous cancers. Late presentation of patients of skin malignancy leads to late detection of the disease. Lack of standardized imaging modalities for skin cancers. Multiple treatment options to choose from. The need for reconstructive surgery for the areas of aesthetic concern. Need for chemotherapy and radiotherapy for treatment. Need for regular follow up. These challenges further add up in the light of COVID-19 because Skin cancers are more prevalent in elderly age group patients, who are also high-risk group for COVID-19.[7] Skin cancer patients may have co-existing immune concerns. They may need multiple visits and follow-up which will increase the chance of infection and cross-infection. Patients needing surgical procedure and reconstruction procedure have more risk of infection and cross-infection. The patients undergoing laser therapy, plume evacuation deserve a special concern.[8] Some patients may need systemic chemotherapy, immune modulators, and radiotherapy, which may further decrease their immunity and increase the risk of severe infection.[9] Avoiding treatment for these patients may lead to progression and incurable systemic disease. Patients needing reconstruction for post cancer ablation need to be operated in a timely manner to prevent additional functional morbidity. Some recommendations suggested are given in Table 1.[1011]
Table 1

Suggested recommendation for management of cutaneous cancers

Type of cancerAge groupRecommendation
Very low riskAny ageTreatment can be postponed for 3 months, telemedicine consultations and follow-up can be done if there is a change in clinical appearance
Precursor lesion,actinic keratosis, leukoplakia, cutaneous horns
Low riskAny age Treatment can be postponed for 4 weeks, telemedicine consultations and follow-up can be done if there is a change in clinical appearance.
Low-grade basal cell carcinoma. Bowen’s disease. Marjolijn ulcers
Moderate riskAny ageComorbidities absentComorbidities present
High-grade BCC, SQCC. Low-grade DFSP sebaceous carcinomaProceed to surgery within days, strict infection control protocolSurgery within days can be done with strict infection control protocol; isolated mobile surgical area
High risk<49Comorbidities absentComorbidities present
Melanoma Merkel cell carcinoma. Recurrent SQCC. High-grade DFSPSurgery within days with strict infection control protocolSurgery and management should be started with strict infection control protocol and isolation mobile surgical area
50–69Comorbidities absent
Surgery within days with strict infection control protocol
>70Comorbidities absentComorbidities present
Decision based on clinical condition of the patient, mobile surgical areaDecision based on clinical condition of the patient, mobile surgical area. Palliative care when poor general condition

BCC = basal cell carcinoma; DFSP = dermatofibrosarcoma protuberans; SQCC = squamous cell carcinoma.

Suggested recommendation for management of cutaneous cancers BCC = basal cell carcinoma; DFSP = dermatofibrosarcoma protuberans; SQCC = squamous cell carcinoma.

Patient who are undergoing systemic treatment

Many hospitals screen the patients on the basis of history and then proceed.

Radiotherapy

For SCC and BCC postponement of RT, clinical observation is recommended. For melanoma, it is advised to continue the treatment if intent is curative. Palliative therapy can be postponed.[12]

Chemotherapy

If treatment is already started, continuation of treatment is advised, while palliative chemotherapy may be deferred. Individualized decision may be taken for each patient.[13]

Immunomodulators

On the basis of clinical factors, response, tumor biology and patient condition, the immunomodulators should be used. There are insufficient data to derive a conclusive evidence. However, TNF-alpha inhibitors have increased risk than others.[14]

CONSIDERATIONS

Patients

Patients with suggestive symptoms, travel history, and contacts should be screened for COVID-19. Some centers also suggest blanket screening of all the patients admitted for non-COVID-19 conditions. A strict policy regarding patient visitors should be enforced. Patients with comorbidities and elderly should be kept in isolated facilities.[15]

Healthcare workers

All healthcare personnel should be trained and informed about the disease transmission, donning, doffing, and knowledge about screening as soon as possible. Video tutorials can be arranged for these methods instead of physical gatherings.[16] It is of utmost importance to protect healthcare workers in the face of limited resources. It is recommended to protect the skin and mucosa which come in contact with patient’s infected body fluids. As the respiratory droplets are crucial for COVID-19 transmission, N-95 masks should be used along with face shields (National Institute for Occupational Safety and Health standard).[17]

Equipment and logistics

Shortage of medical resources and manpower is unavoidable, a rational use is mandatory, and a dedicated equipment and operation facility should be reserved for COVID patients to prevent cross-infection.[7]

Hospital and environment

Cleaning and disinfection of potential areas of high contamination should be done by 1% hypochlorite solution. Planning of routes of patient transport, changes in systems of air circulation, and avoidance of crowding are other important factors for infection control.[18]

Management of cutaneous cancers

Skin cancers usually do not present as emergency condition. However, owing to the nature of aggressive malignancy, sometimes early surgical management is needed with curative intent. In continuation, patients with facial malignancy also need to be operated to prevent possible suboptimal aesthetic and functional outcome. Surgical excision and repair provide superior aesthetic outcome as compared to ablative and topical treatments.[19] However, during COVID-19 pandemic, when many surgical procedures have been put on hold, topical immunomodulators may be considered where indicated. Nevertheless, each clinical scenario should be weighed on pros and cons by the clinician before the treatment commencement.

Use of technology

The use of telemedicine and video call facilities for consultations of the patients, or multispecialty decision making, e.g. tumor board, can be considered.[2021] Artificial intelligence-driven mobile applications can be used for follow-up and counseling.[22]

CONCLUSION

The whole world is going through a difficult period with stagnancy in most of the aspects of life. Care of skin malignancy during this period deserves due consideration with application of clinical logic. Optimal patient care along with safety of the healthcare workers is an absolute priority (the safety of health care workers is crucial along with providing optimal patient care). Designing and planning the healthcare system with judicious use of resources is important in adequate management of skin malignancies.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  16 in total

1.  A retrospective comparative study of outcome with surgical excision and repair versus nonsurgical and ablative treatments for basal cell carcinoma.

Authors:  Soniya Mahajan; Mani Kalaivani; Gomathy Sethuraman; Binod Kumar Khaitan; Kaushal Kumar Verma; Somesh Gupta
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 May-Jun       Impact factor: 2.545

2.  Significant impairment in immune recovery after cancer treatment.

Authors:  Duck-Hee Kang; Michael T Weaver; Na-Jin Park; Barbara Smith; Traci McArdle; John Carpenter
Journal:  Nurs Res       Date:  2009 Mar-Apr       Impact factor: 2.381

3.  Use of Smartphones for Early Detection of Melanoma: Systematic Review.

Authors:  Cédric Rat; Sandrine Hild; Julie Rault Sérandour; Aurélie Gaultier; Gaelle Quereux; Brigitte Dreno; Jean-Michel Nguyen
Journal:  J Med Internet Res       Date:  2018-04-13       Impact factor: 5.428

4.  Automated detection of nonmelanoma skin cancer using digital images: a systematic review.

Authors:  Arthur Marka; Joi B Carter; Ermal Toto; Saeed Hassanpour
Journal:  BMC Med Imaging       Date:  2019-02-28       Impact factor: 1.930

5.  Population-Level Interest and Telehealth Capacity of US Hospitals in Response to COVID-19: Cross-Sectional Analysis of Google Search and National Hospital Survey Data.

Authors:  Young-Rock Hong; John Lawrence; Dunc Williams; Arch Mainous III
Journal:  JMIR Public Health Surveill       Date:  2020-04-07

6.  COVID-19: Global radiation oncology's targeted response for pandemic preparedness.

Authors:  Richard Simcock; Toms Vengaloor Thomas; Christopher Estes; Andrea R Filippi; Matthew A Katz; Ian J Pereira; Hina Saeed
Journal:  Clin Transl Radiat Oncol       Date:  2020-03-24

7.  Safety testing improvised COVID-19 personal protective equipment based on a modified full-face snorkel mask.

Authors:  P R Greig; C Carvalho; K El-Boghdadly; S Ramessur
Journal:  Anaesthesia       Date:  2020-04-19       Impact factor: 12.893

8.  A War on Two Fronts: Cancer Care in the Time of COVID-19.

Authors:  Alexander Kutikov; David S Weinberg; Martin J Edelman; Eric M Horwitz; Robert G Uzzo; Richard I Fisher
Journal:  Ann Intern Med       Date:  2020-03-27       Impact factor: 25.391

9.  Coronavirus Disease 2019 (COVID-19) and dermatologists: Potential biological hazards of laser surgery in epidemic area.

Authors:  Seyed-Naser Emadi; Bahareh Abtahi-Naeini
Journal:  Ecotoxicol Environ Saf       Date:  2020-04-06       Impact factor: 6.291

10.  Telemedicine in the Era of COVID-19.

Authors:  Jay Portnoy; Morgan Waller; Tania Elliott
Journal:  J Allergy Clin Immunol Pract       Date:  2020-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.